Multiple Myeloma Challenges and Treatment Evolution

EP: 1.Pharmacists in Multiple Myeloma Care: Essential Roles and Patient Support

EP: 2.Eligibility Factors in Multiple Myeloma Transplant

EP: 3.Multiple Myeloma Care: Pharmacist Team Collaboration

EP: 4.Multiple Myeloma Regimen Comparisons

EP: 5.Pharmacist's Role in Enhancing Multiple Myeloma Care

EP: 6.Choosing Multiple Myeloma Regimens

EP: 7.Pharmacists' Patient Counseling Role

EP: 8.Advanced Multiple Myeloma Treatments

EP: 9.Pharmacist-Led Care Transitions: Best Practices

Now Viewing

EP: 10.Multiple Myeloma Challenges and Treatment Evolution

This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.

Hinojosa highlighted the prominent unmet need in multiple myeloma management: the absence of a cure and eventual exhaustion of treatment options. Despite recent additions to the treatment arsenal, achieving a cure remains elusive. The treatment landscape is evolving with the identification of new targets such as BCMA and GPRC5D, offering promising response rates. Bispecifics and chimeric antigen receptor T-cell agents have revolutionized patient treatment, with more in the pipeline, requiring continuous exploration of optimal sequencing and toxicity management. Social determinants of health significantly impact outcomes, especially for patients with lower incomes and limited resources, leading to challenges in medication adherence, treatment schedules, and financial toxicity. Addressing these social determinants is a crucial unmet need to enhance overall care for patients with multiple myeloma.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.